Johnson & Johnson wins FDA approval for dual-energy Thermocool Smarttouch SF ablation platform
Johnson & Johnson has received U.S. Food and Drug Administration approval for the Dual Energy Thermocool Smarttouch SF Platform, an integrated cardiac ablation system that allows electrophysiologists to deliver both radiofrequency and pulsed field energy through a single catheter. The approval places the Johnson & Johnson MedTech electrophysiology business into a more direct U.S. rollout